Audeo Oncology (Audeo Oncology) Accounts Receivable : $0.00 Mil (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Audeo Oncology's accounts receivables for the quarter that ended in Sep. 2012 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Audeo Oncology's Days Sales Outstanding for the quarter that ended in Sep. 2012 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Audeo Oncology's Net-Net Working Capital per share for the quarter that ended in Sep. 2012 was $N/A.

Audeo Oncology Accounts Receivable Historical Data

The historical data trend for Audeo Oncology's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Accounts Receivable Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Accounts Receivable

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Accounts Receivable	-	-	-	-

Audeo Oncology Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Audeo Oncology Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Audeo Oncology's Days Sales Outstanding for the quarter that ended in Sep. 2012 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.061	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Audeo Oncology's accounts receivable are only considered to be worth 75% of book value:

Audeo Oncology's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2012 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.524	+	0.75 * 0	+	0.5 * 0	-	5.744
-	0	-	0)	/	0
=	N/A

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Audeo Oncology Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Accounts Receivable

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.